Scarica l'app Stockscreener
0.3767
1.11%
0.0093
Elevation Oncology Inc Borsa (ELEV) Ultime notizie
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech - BioPharma Dive
Elevation mulls strategic alternatives, including closure, amid activist pressure - PharmaLive
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $3.39 - Defense World
Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Pfizer sells site, cuts staff - Fierce Biotech
Rare NRG1 Fusion Market to Reach New Heights in Growth by 2034, - openPR.com
Elevation Oncology opts for early term loan repayment By Investing.com - Investing.com South Africa
Elevation Oncology opts for early term loan repayment - Investing.com
Elevation Oncology IncTo Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022SEC Filing - MarketScreener
Elevation Oncology stock hits 52-week low at $0.24 By Investing.com - Investing.com Canada
Virtu Financial LLC Takes $36,000 Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology’s Chief Medical Officer Steps Down - TipRanks
What is Elevation Oncology Inc (ELEV) Stock Return on Shareholders’ Capital? - Sete News
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Longview News-Journal
Breakthrough Cancer Drug Shows Promise: First Look at EO-1022 Data for Breast and Lung Cancer - Stock Titan
Elevation Oncology (NASDAQ:ELEV) Given “Equal Weight” Rating at Stephens - Defense World
Analysts Set Expectations for ELEV FY2029 Earnings - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Neutral” at Piper Sandler - The AM Reporter
Massachusetts-Based Elevation Oncology Cuts 70% of Workforce After Drug Setback - NewsBreak: Local News & Alerts
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to “Market Perform” at Citizens Jmp - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Neutral at Piper Sandler - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Market Perform at Leerink Partners - Defense World
HC Wainwright Lowers Elevation Oncology (NASDAQ:ELEV) Price Target to $1.00 - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at Leerink Partnrs - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to Hold at Wedbush - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $6.83 Average Target Price from Analysts - Defense World
Elevation Oncology Plunges 42% on Ending Development of Lead Drug - MSN
Elevation Oncology stock rating cut amid ADC asset halt By Investing.com - Investing.com Canada
Elevation Oncology Plunges 42% On Ending Development Of Lead Drug - Barchart
Boston cancer biotech cuts 70% of staff - The Business Journals
Elevation Oncology downgraded as it halts lead asset on disappointing trials - Yahoo Finance
Tesla To $410? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Piper Sandler Downgrades Elevation Oncology to Neutral From Overweight, Adjusts Price Target to $0.70 From $10 - Marketscreener.com
Piper Sandler cuts Elevation Oncology stock rating to Neutral By Investing.com - Investing.com Canada
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70% - Benzinga
Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding - Endpoints News
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results - Benzinga
Elevation Oncology, Inc. Implements A Workforce Reduction of Approximately 70% -March 20, 2025 at 08:08 am EDT - Marketscreener.com
Elevation Oncology halts development of cancer drug EO-3021 By Investing.com - Investing.com Australia
Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView
Elevation Oncology tumbles after halting development of cancer drug - TradingView
Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell - Marketscreener.com
Why Is Elevation Oncology Stock Falling In Pre-market? - Nasdaq
Elevation Oncology stock tumbles on halted drug development By Investing.com - Investing.com Canada
Elevation Oncology Restructures Amid EO-3021 Discontinuation - TipRanks
Elevation Oncology stock tumbles on halted drug development - Investing.com India
Elevation Oncology halts development of cancer drug EO-3021 - Investing.com India
0.77%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):